An Illinois federal judge canned a $140 million verdict against AbbVie and ordered a new trial involving its testosterone replacement therapy, AndroGel, after ruling the jury’s findings were contradictory.
Source: Drug Industry Daily
An Illinois federal judge canned a $140 million verdict against AbbVie and ordered a new trial involving its testosterone replacement therapy, AndroGel, after ruling the jury’s findings were contradictory.
Source: Drug Industry Daily